Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022

SELL
$31.92 - $47.45 $464,946 - $691,156
-14,566 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$26.23 - $47.86 $382,066 - $697,128
14,566 New
14,566 $678,000

Others Institutions Holding ITOS

About iTeos Therapeutics, Inc.


  • Ticker ITOS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,575,300
  • Market Cap $257M
  • Description
  • Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...
More about ITOS
Track This Portfolio

Track Fifth Lane Capital, LP Portfolio

Follow Fifth Lane Capital, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fifth Lane Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Fifth Lane Capital, LP with notifications on news.